

ØSMM&N File No. <u>0660-0158-0 PCT</u>

Dept.: Chemical

By: NFO/TMC/krs

Serial No. 09/367,703

to the matter of the Application of: Catherine ROUGEOT, et al.

For: THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE

DERIVATIVES THEREOF

Due Date: n/a

The following has been received in the U.S. Patent Office on the date stamped hereon:

- Dep. Acct. Order Form
- PTO Cover Letter
- Sequence Listing (Paper; 7 pp.)
- Computer-Readable Sequence Listing (Diskette)
- Statement

COPY

OS NON - 6 FH 9: SH

Docket No.: 0660-0158-0 PCT



OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT P.C.

ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/367,703

Applicants: Catherine ROUGEOT, et al.

Filing Date: October 13, 1999

For: THERAPEUTIC USE OF THE SMR1 PROTEIN AND

ACTIVE DERIVATIVES THEREOF

Group Art Unit: 1642 Examiner: K. Canella

SIR:

Attached hereto for filing are the following papers:

Sequence Listing (Paper; 7 pp.); Computer-Readable Sequence Listing (Diskette); Statement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Thomas M. Cunningham Registration No. 45,394



(703) 413-3000 (phone) (703) 413-2220 (fax)



Docket No.

240156US0DIV

IN RE APPLICATION OF: Catherine ROUGEOT, et al.

SERIAL NO: 10/620,462

FILED: FOR:

July 17, 2003 THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Transmitted herewith is a supplemental preliminary amendment in the above-identified application.

- ☐ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- Additional documents filed herewith:

Statement Regarding Sequence Listing; Substitute Specification (79 pp.); Copy of Receipt Card (filed 11-6-02); Copy of PTO Cover Letter (filed 11-6-02); Copy of Statement Under 37 C.F.R. 1.821(F)-(G) (filed 11-6-02); Copy of Sequence Listing (filed 11-6-02)

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS		RATE		CALCULATIONS
TOTAL	27	MINUS	27	0	х	\$18	-	\$0.00
INDEPENDENT	3	MINUS	3	0	х	\$84	=	\$0.00
	1	☐ MULTIPLE DEPENDENT CLAIMS + \$280 =					=	\$0.00
	TOTAL OF ABOVE CALCULATIONS					ONS	\$0.00	
**		☐ Reduction by 50% for filing by Small Entity					\$0.00	
☐ Recordation of Assignment +				\$40	=	\$0.00		
					_	TO	ΓAL	\$0.00

	Α	check	in	the	amo	int o	f \$0.	.00	is	attache	d.
--	---	-------	----	-----	-----	-------	--------	-----	----	---------	----

- ☐ Credit card payment form is attached to cover the fees in the amount of <u>\$0.00</u>
- Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No.

24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Thomas M. Cunningham

Registration No. 45,394